Accreditation

0.5 AMA PRA Category 1 Credit(s)™.
Read the full Accreditation Statement

Target Audience

Researchers and clinicians (rheumatologists, gastroenterologists, dermatologists, and pulmonologists) involved with autoimmune and inflammatory disorders and, in particular, those with an interest in the field of TNF inhibitor therapy.

Activity Design

Each lesson within the Managing the Problem Patient with Anti-TNF Inhibitors: Infectious, Malignant, Neurologic and Other Complex Issues Series includes a problem case, summary & recommendations, summary article, post-test and an evaluation.

Upon completing the CME activity, the evaluation and registration forms, you will have an opportunity to print your CME certficate for your records.

Objectives

At the conclusion of this activity, the participant will be able to:

1. Recognize the relationship between opportunistic infection and TNF inhibitor therapy.
2. Describe the role of TNF in the pathogenesis of cryptococcal infection.
3. Identify the key issues relevant to the appropriate management of patients developing cryptococcal and other opportunistic infection during TNF inhibitor therapy.

Co-Activity Directors

Nizar N. Zein, MD
Director of Clinical Hepatology
Department of Gastroenterology & Hepatology
Digestive Disease Center
The Cleveland Clinic
Cleveland, Ohio

Leonard H. Calabrese, DO
Vice Chairman, Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair in Clinical Immunology
The Cleveland Clinic
Cleveland, Ohio

Author

E. William St. Clair, MD

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

E. William St. Clair, MD — Grant: Amgen, Centocor, Genentech, IDEC; Pharmaceuticals Consultant: Bristol-Myers Squibb, Genentech, Human Genome Sciences

Leonard H. Calabrese, DO — Consulting, Teaching and Speaking: Abbott, Amgen-Wyeth